应交易所要求,美/港股行情延时15分钟展示,下载APP即可免费查看实时行情。
关闭
03378 翰思艾泰-B
已收盘 07-23 16:08:04
26.900
+0.100
+0.37%
最高
27.000
最低
25.500
成交量
2.13万
今开
27.000
昨收
26.800
日振幅
5.60%
总市值
36.05亿
流通市值
36.05亿
总股本
1.34亿
成交额
55.38万
换手率
0.02%
流通股本
1.34亿
市净率
--
ROE
--
每股收益
0.00
52周最高
--
52周最低
--
市盈率
--
股息
--
股息收益率
--
ROA
--
分时
五日
日K
周K
月K
数据加载中...
北京优虎网络科技有限公司
免责声明:香港交易所资讯服务有限公司、其控股公司及/或该等控股公司的任何附属公司均竭力确保所提供信息的准确和可靠度,但不能保证其绝对准确和可靠,且亦不会承担因任何不准确或遗漏而引起的任何损失或损害的责任(不管是否侵权法下的责任或合约责任又或其它责任)
资讯
新帖
简况
翰思艾泰-B(03378.HK)7月17日斥资171.99万港元回购6.05万股
智通财经 · 07-17
翰思艾泰-B(03378.HK)7月17日斥资171.99万港元回购6.05万股
翰思艾泰-B于7月17日回购6.05万股,涉资约171.99万港元
公告速递 · 07-17
翰思艾泰-B于7月17日回购6.05万股,涉资约171.99万港元
翰思艾泰-B 7月16日回购15,600股股份,耗资约45.38万港元
公告速递 · 07-16
翰思艾泰-B 7月16日回购15,600股股份,耗资约45.38万港元
翰思艾泰-B回购5.57万股股份,总额约161.26万港元
公告速递 · 07-15
翰思艾泰-B回购5.57万股股份,总额约161.26万港元
翰思艾泰-B(03378.HK)7月15日斥资161.26万港元回购5.57万股
智通财经 · 07-15
翰思艾泰-B(03378.HK)7月15日斥资161.26万港元回购5.57万股
翰思艾泰-B 7月14日回购5.82万股,涉资约168.49万港元
公告速递 · 07-14
翰思艾泰-B 7月14日回购5.82万股,涉资约168.49万港元
翰思艾泰-B(03378.HK)7月14日斥资168.49万港元回购5.82万股
智通财经 · 07-14
翰思艾泰-B(03378.HK)7月14日斥资168.49万港元回购5.82万股
翰思艾泰-B 7月13日回购4.57万股,耗资约132.46万港元
公告速递 · 07-13
翰思艾泰-B 7月13日回购4.57万股,耗资约132.46万港元
翰思艾泰-B(03378.HK)7月13日斥资约132.46万港元回购4.57万股
智通财经 · 07-13
翰思艾泰-B(03378.HK)7月13日斥资约132.46万港元回购4.57万股
翰思艾泰-B回购41,400股股份,总额约119.91万港元
公告速递 · 07-10
翰思艾泰-B回购41,400股股份,总额约119.91万港元
翰思艾泰-B(03378.HK)7月10日斥资119.9万港元回购4.14万股
智通财经 · 07-10
翰思艾泰-B(03378.HK)7月10日斥资119.9万港元回购4.14万股
翰思艾泰-B:7月9日回购3.64万股,耗资约104.20万港元
公告速递 · 07-09
翰思艾泰-B:7月9日回购3.64万股,耗资约104.20万港元
翰思艾泰-B(03378)7月8日斥资98.01万港元回购3.38万股
智通财经 · 07-08
翰思艾泰-B(03378)7月8日斥资98.01万港元回购3.38万股
翰思艾泰-B回购3.38万股股份,总额约98.01万港元
公告速递 · 07-08
翰思艾泰-B回购3.38万股股份,总额约98.01万港元
翰思艾泰-B:7月7日回购2.1万股,耗资约60.70万港元
公告速递 · 07-07
翰思艾泰-B:7月7日回购2.1万股,耗资约60.70万港元
翰思艾泰-B(03378)7月7日斥资60.7万港元回购2.1万股
智通财经 · 07-07
翰思艾泰-B(03378)7月7日斥资60.7万港元回购2.1万股
翰思艾泰-B(03378.HK)7月7日斥资60.7万港元回购2.1万股
智通财经 · 07-07
翰思艾泰-B(03378.HK)7月7日斥资60.7万港元回购2.1万股
翰思艾泰-B与合作伙伴签署协议,共建人工智能驱动的药物发现联合实验室
美股速递 · 07-07
翰思艾泰-B与合作伙伴签署协议,共建人工智能驱动的药物发现联合实验室
翰思艾泰-B与华科-城大澳门高等跨学科研究中心达成合作
美股速递 · 07-07
翰思艾泰-B与华科-城大澳门高等跨学科研究中心达成合作
翰思艾泰-B(03378):拟与华科前沿交叉研究中心打造新一代AI驱动的创新药研发范式
智通财经 · 07-07
翰思艾泰-B(03378):拟与华科前沿交叉研究中心打造新一代AI驱动的创新药研发范式
加载更多
公司概况
公司名称:
翰思艾泰-B
所属市场:
SEHK
上市日期:
--
主营业务:
翰思艾泰生物医药科技(武汉)股份有限公司是一家主要从事肿瘤免疫疗法的研发的中国公司。该公司的产品管线有针对肿瘤学的临床阶段候选药物和临床前阶段候选药物,包括核心产品HX009及主要产品HX301及HX044,以及针对自身免疫和肿瘤市场的抗体偶联药物、双特异性抗体及单克隆抗体。HX009是一种自主研发的抗程序性细胞死亡蛋白1(PD-1)/信号调节蛋白α(SIRPα)双功能抗体融合蛋白。HX301是一种靶向集落刺激因子-1受体(CSF1R)、AMPK相关蛋白激酶5(ARK5)、FMS样酪氨酸激酶3(FLT-3)及细胞周期蛋白依赖性激酶4/6(CDK4/6)等关键通路的多靶点激酶抑制剂。HX044为一种新型双重功能抗细胞毒性T淋巴细胞相关蛋白4(CTLA-4)抗体SIRPα融合蛋白。
发行价格:
--
{"stockData":{"symbol":"03378","market":"HK","secType":"STK","nameCN":"翰思艾泰-B","latestPrice":26.9,"timestamp":1784794084435,"preClose":26.8,"halted":0,"volume":21300,"delay":0,"changeRate":0.00373134328358201,"floatShares":134000000,"shares":134000000,"eps":-1.11,"marketStatus":"已收盘","change":0.1,"latestTime":"07-23 16:08:04","open":27,"high":27,"low":25.5,"amount":553794,"amplitude":0.05597,"askPrice":26.9,"askSize":1700,"bidPrice":26,"bidSize":2000,"shortable":0,"etf":0,"ttmEps":-1.077,"tradingStatus":0,"nextMarketStatus":{"tag":"开盘","tradingStatus":2,"beginTime":1784856600000},"marketStatusCode":5,"adr":0,"listingDate":1766419200000,"exchange":"SEHK","adjPreClose":26.8,"openAndCloseTimeList":[[1784770200000,1784779200000],[1784782800000,1784793600000]],"volumeRatio":0.409301,"lotSize":100,"spreadScale":0,"tradeCurrency":"HKD","astockBrief":{"symbol":"000905","market":"SZ","secType":"STK","nameCN":"厦门港务","latestPrice":8.57,"timestamp":1784790000000,"preClose":8.01,"halted":0,"volume":18665500,"delay":0,"premium":"+171.19"}},"requestUrl":"/m/hq/s/03378","defaultTab":"news","newsList":[{"id":"2652400436","title":"翰思艾泰-B(03378.HK)7月17日斥资171.99万港元回购6.05万股","url":"https://stock-news.laohu8.com/highlight/detail?id=2652400436","media":"智通财经","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2652400436?lang=zh_cn&edition=full","pubTime":"2026-07-17 19:38","pubTimestamp":1784288282,"startTime":"0","endTime":"0","summary":null,"market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.zhitongcaijing.com/immediately.html?type=ganggu","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"live_zhitongcaijing","symbols":["03378","BK1535","BK1173","BK1161"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1152145952","title":"翰思艾泰-B于7月17日回购6.05万股,涉资约171.99万港元","url":"https://stock-news.laohu8.com/highlight/detail?id=1152145952","media":"公告速递","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/1152145952?lang=zh_cn&edition=full","pubTime":"2026-07-17 19:35","pubTimestamp":1784288152,"startTime":"0","endTime":"0","summary":"翰思艾泰生物医药科技(武汉)股份有限公司于2026年7月17日公告称,公司在香港联交所场内回购60,500股H股股份,约占回购前已发行股本的0.045%。本次回购价介乎每股27.42港元至29.50港元,合计耗资1,719,928港元。公司于2026年6月24日召开会议通过了本次回购授权,授权回购股份总数为13,469,683股。截至本次回购完成,公司已累计回购636,100股,占授权当日已发行股本总数的0.4722%。","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":"翰思艾泰-B于7月17日回购6.05万股,涉资约171.99万港元","news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["03378"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1187738660","title":"翰思艾泰-B 7月16日回购15,600股股份,耗资约45.38万港元","url":"https://stock-news.laohu8.com/highlight/detail?id=1187738660","media":"公告速递","labels":["shareholding","SGX"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/1187738660?lang=zh_cn&edition=full","pubTime":"2026-07-16 18:33","pubTimestamp":1784198002,"startTime":"0","endTime":"0","summary":"翰思艾泰生物医药科技(武汉)股份有限公司于2026年7月16日发布翌日披露报表,披露其于当日于香港联交所场内回购15,600股H股普通股。该数量约占回购前公司已发行股份总数134,136,830股的0.012%,回购价介乎每股28.94港元至29.68港元,合计耗资约45.38万港元。回购完成后,公司已发行股本变动为134,121,230股,库存股份增加至2,097,600股。根据公告,股东大会已于2026年6月24日通过股份购回授权,总额度为13,469,683股。","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":"翰思艾泰-B 7月16日回购15,600股股份,耗资约45.38万港元","news_tag":"shareholding,SGX","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["03378"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1111871776","title":"翰思艾泰-B回购5.57万股股份,总额约161.26万港元","url":"https://stock-news.laohu8.com/highlight/detail?id=1111871776","media":"公告速递","labels":["shareholding","SGX"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/1111871776?lang=zh_cn&edition=full","pubTime":"2026-07-15 19:35","pubTimestamp":1784115358,"startTime":"0","endTime":"0","summary":"翰思艾泰生物医药科技(武汉)股份有限公司于2026年7月15日公告,披露公司在香港联交所场内回购股份。此次回购涉及5.57万股,占回购前公司已发行股本约0.042%。回购价介乎每股28.66港元至29.90港元,总代价约为161.26万港元。回购完成后,公司已发行股本总数维持136,218,830股,库藏股增至2,082,000股。根据公告,公司回购授权于2026年6月24日获股东大会通过,可回购总数为13,469,683股。截至目前,公司已通过香港联交所及其他证券交易所累计回购560,000股,剩余授权额度为12,909,683股。","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":"翰思艾泰-B回购5.57万股股份,总额约161.26万港元","news_tag":"shareholding,SGX","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["03378"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2651450359","title":"翰思艾泰-B(03378.HK)7月15日斥资161.26万港元回购5.57万股","url":"https://stock-news.laohu8.com/highlight/detail?id=2651450359","media":"智通财经","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2651450359?lang=zh_cn&edition=full","pubTime":"2026-07-15 19:33","pubTimestamp":1784115186,"startTime":"0","endTime":"0","summary":null,"market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.zhitongcaijing.com/immediately.html?type=ganggu","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"live_zhitongcaijing","symbols":["03378","BK1173","BK1535","BK1161"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1184011115","title":"翰思艾泰-B 7月14日回购5.82万股,涉资约168.49万港元","url":"https://stock-news.laohu8.com/highlight/detail?id=1184011115","media":"公告速递","labels":["shareholding","SGX"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/1184011115?lang=zh_cn&edition=full","pubTime":"2026-07-14 19:35","pubTimestamp":1784028947,"startTime":"0","endTime":"0","summary":"翰思艾泰生物医药科技(武汉)股份有限公司于2026年7月14日回购公司股份。据公告披露,本次回购数量为58,200股,占该事件前公司已发行股本约0.043%。回购价格区间介乎每股28.5港元至29.88港元,合计支付约168.49万港元。本次回购完成后,截至2026年7月14日收市,公司已发行股本数量由回购前的134,250,730股减少至134,192,530股,库藏股数量由1,968,100股增至2,026,300股,总发行股本仍为136,218,830股。公司同时确认已经遵守相关上市规则及适用法律规定。","market":"sh","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":"翰思艾泰-B 7月14日回购5.82万股,涉资约168.49万港元","news_tag":"shareholding,SGX","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["03378"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2651170465","title":"翰思艾泰-B(03378.HK)7月14日斥资168.49万港元回购5.82万股","url":"https://stock-news.laohu8.com/highlight/detail?id=2651170465","media":"智通财经","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2651170465?lang=zh_cn&edition=full","pubTime":"2026-07-14 19:26","pubTimestamp":1784028404,"startTime":"0","endTime":"0","summary":null,"market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.zhitongcaijing.com/immediately.html?type=ganggu","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"live_zhitongcaijing","symbols":["BK1173","03378","BK1161","BK1535"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1104304706","title":"翰思艾泰-B 7月13日回购4.57万股,耗资约132.46万港元","url":"https://stock-news.laohu8.com/highlight/detail?id=1104304706","media":"公告速递","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/1104304706?lang=zh_cn&edition=full","pubTime":"2026-07-13 18:51","pubTimestamp":1783939908,"startTime":"0","endTime":"0","summary":"翰思艾泰生物医药科技(武汉)股份有限公司于2026年7月13日发布公告披露,公司当日在香港联合交易所回购H股45,700股,占回购前公司已发行股份的约0.034%,回购价格区间为每股28.48港元至30.00港元,总支付金额约132.46万港元。本次回购完成后,公司已发行股份由2026年7月10日的134,296,430股降至134,250,730股,库存股份则由1,922,400股增至1,968,100股,合计已发行股份维持在136,218,830股。根据此前于2026年6月24日获得股东大会批准的购回授权,公司可回购股份总数为13,469,683股。","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":"翰思艾泰-B 7月13日回购4.57万股,耗资约132.46万港元","news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["03378"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2651153261","title":"翰思艾泰-B(03378.HK)7月13日斥资约132.46万港元回购4.57万股","url":"https://stock-news.laohu8.com/highlight/detail?id=2651153261","media":"智通财经","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2651153261?lang=zh_cn&edition=full","pubTime":"2026-07-13 18:51","pubTimestamp":1783939881,"startTime":"0","endTime":"0","summary":null,"market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.zhitongcaijing.com/immediately.html?type=ganggu","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"live_zhitongcaijing","symbols":["03378","BK1161","BK1535","BK1173"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1113904050","title":"翰思艾泰-B回购41,400股股份,总额约119.91万港元","url":"https://stock-news.laohu8.com/highlight/detail?id=1113904050","media":"公告速递","labels":["shareholding","SGX"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/1113904050?lang=zh_cn&edition=full","pubTime":"2026-07-10 19:20","pubTimestamp":1783682451,"startTime":"0","endTime":"0","summary":"翰思艾泰生物医药科技(武汉)股份有限公司于2026年7月10日发布公告,披露在香港联交所进行的股份购回情况。本次于2026年7月10日回购41,400股H股,占公司当日回购前已发行股本约0.031%,每股价格介乎每股28.4港元至30港元,总涉资约119.91万港元。购回完成后,公司已发行股份总数维持在136,218,830股,其中1,922,400股为库存股份,未计入库存股份的已发行股数为134,296,430股。截至目前,公司已累积回购400,400股,占授权获通过当日已发行股本总数的约0.2973%。","market":"hk","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":"翰思艾泰-B回购41,400股股份,总额约119.91万港元","news_tag":"shareholding,SGX","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["03378"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2650919182","title":"翰思艾泰-B(03378.HK)7月10日斥资119.9万港元回购4.14万股","url":"https://stock-news.laohu8.com/highlight/detail?id=2650919182","media":"智通财经","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2650919182?lang=zh_cn&edition=full","pubTime":"2026-07-10 19:19","pubTimestamp":1783682384,"startTime":"0","endTime":"0","summary":null,"market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.zhitongcaijing.com/immediately.html?type=ganggu","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"live_zhitongcaijing","symbols":["BK1173","BK1161","03378","BK1535"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1176651071","title":"翰思艾泰-B:7月9日回购3.64万股,耗资约104.20万港元","url":"https://stock-news.laohu8.com/highlight/detail?id=1176651071","media":"公告速递","labels":["shareholding","SGX"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/1176651071?lang=zh_cn&edition=full","pubTime":"2026-07-09 18:00","pubTimestamp":1783591257,"startTime":"0","endTime":"0","summary":"翰思艾泰生物医药科技(武汉)股份有限公司于2026年7月9日发布公告,当日回购公司股份36,400股,占此前已发行股本约0.027%。最高回购价为每股28.9港元,最低回购价为每股28港元,总交易金额1,042,004港元,折合约104.20万港元。回购授权于2026年6月24日获股东大会通过,授权购回股份总数为13,469,683股;截至目前,已合计回购359,000股。公司确认,上述回购事项已获董事会正式授权并遵守相关上市规则与法律规定。本公告由董事长兼执行董事张发明签署。","market":"hk","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":"翰思艾泰-B:7月9日回购3.64万股,耗资约104.20万港元","news_tag":"shareholding,SGX","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["03378"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2649963679","title":"翰思艾泰-B(03378)7月8日斥资98.01万港元回购3.38万股","url":"https://stock-news.laohu8.com/highlight/detail?id=2649963679","media":"智通财经","labels":["shareholding"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2649963679?lang=zh_cn&edition=full","pubTime":"2026-07-08 20:43","pubTimestamp":1783514619,"startTime":"0","endTime":"0","summary":"智通财经APP讯,翰思艾泰-B(03378)发布公告,该公司于2026年7月8日斥资98.01万港元回购3.38万股股份,每股回购价格为28.42-30港元。","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://www.zhitongcaijing.com/content/detail/1464925.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"shareholding","news_rank":0,"length":0,"strategy_id":0,"source":"stock_zhitongcaijing","symbols":["BK1173","BK1161","03378","BK1535"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1126495734","title":"翰思艾泰-B回购3.38万股股份,总额约98.01万港元","url":"https://stock-news.laohu8.com/highlight/detail?id=1126495734","media":"公告速递","labels":["shareholding","SGX"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/1126495734?lang=zh_cn&edition=full","pubTime":"2026-07-08 20:36","pubTimestamp":1783514165,"startTime":"0","endTime":"0","summary":"翰思艾泰生物医药科技(武汉)股份有限公司于2026年7月8日回购H股普通股3.38万股,占回购前公司已发行股份总数的约0.025%。每股回购价介乎28.42港元至30.00港元,合共支付约98.01万港元。回购完成后,公司已发行股份数目变更为134,374,230股,库藏股数目为1,844,600股,合计已发行股份总数维持在136,218,830股。公司此前于2026年6月24日通过回购授权,当前可回购股份余量为13,469,683股。公司确认已遵守香港联合交易所有限公司证券上市规则及相关法律法规。","market":"sh","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":"翰思艾泰-B回购3.38万股股份,总额约98.01万港元","news_tag":"shareholding,SGX","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["03378"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1197263452","title":"翰思艾泰-B:7月7日回购2.1万股,耗资约60.70万港元","url":"https://stock-news.laohu8.com/highlight/detail?id=1197263452","media":"公告速递","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/1197263452?lang=zh_cn&edition=full","pubTime":"2026-07-07 19:38","pubTimestamp":1783424328,"startTime":"0","endTime":"0","summary":"翰思艾泰生物医药科技(武汉)股份有限公司于2026年7月7日发布公告,披露当日于香港联交所场内回购普通股21,000股,占回购前公司已发行股份总数约0.016%。每股回购价介乎每股28.38港元至29.50港元,合计支付约60.70万港元。回购完成后,公司已发行股份数目由134,429,030股减少至134,408,030股,库藏股数量由1,789,800股增至1,810,800股,发行股份总数维持在136,218,830股不变。本次回购基于公司于2026年6月24日通过的回购授权,授权总额度为13,469,683股。","market":"hk","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":"翰思艾泰-B:7月7日回购2.1万股,耗资约60.70万港元","news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["03378"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2649984224","title":"翰思艾泰-B(03378)7月7日斥资60.7万港元回购2.1万股","url":"https://stock-news.laohu8.com/highlight/detail?id=2649984224","media":"智通财经","labels":["shareholding"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2649984224?lang=zh_cn&edition=full","pubTime":"2026-07-07 19:28","pubTimestamp":1783423708,"startTime":"0","endTime":"0","summary":"智通财经APP讯,翰思艾泰-B(03378)发布公告,于2026年7月7日斥资60.7万港元回购2.1万股。","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://www.zhitongcaijing.com/content/detail/1464287.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"shareholding","news_rank":0,"length":0,"strategy_id":0,"source":"stock_zhitongcaijing","symbols":["03378","BK1161","BK1173","BK1535"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2649222984","title":"翰思艾泰-B(03378.HK)7月7日斥资60.7万港元回购2.1万股","url":"https://stock-news.laohu8.com/highlight/detail?id=2649222984","media":"智通财经","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2649222984?lang=zh_cn&edition=full","pubTime":"2026-07-07 19:28","pubTimestamp":1783423708,"startTime":"0","endTime":"0","summary":null,"market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.zhitongcaijing.com/immediately.html?type=ganggu","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"live_zhitongcaijing","symbols":["BK1535","BK1173","BK1161","03378"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1162631382","title":"翰思艾泰-B与合作伙伴签署协议,共建人工智能驱动的药物发现联合实验室","url":"https://stock-news.laohu8.com/highlight/detail?id=1162631382","media":"美股速递","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/1162631382?lang=zh_cn&edition=full","pubTime":"2026-07-07 19:05","pubTimestamp":1783422332,"startTime":"0","endTime":"0","summary":"翰思艾泰-B已正式签署协议,将携手合作伙伴共同建立一个专注于人工智能技术应用的药物发现联合实验室。此举旨在整合前沿的AI算法与生物医药研发能力,以加速新药的探索与开发进程。","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK1161","BK1535","03378","BK1173"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1159980849","title":"翰思艾泰-B与华科-城大澳门高等跨学科研究中心达成合作","url":"https://stock-news.laohu8.com/highlight/detail?id=1159980849","media":"美股速递","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/1159980849?lang=zh_cn&edition=full","pubTime":"2026-07-07 19:05","pubTimestamp":1783422313,"startTime":"0","endTime":"0","summary":"翰思艾泰-B宣布,与华中科技大学-香港城市大学澳门高等跨学科研究中心建立合作关系。","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK1535","03378","BK1161","BK1173"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2649984355","title":"翰思艾泰-B(03378):拟与华科前沿交叉研究中心打造新一代AI驱动的创新药研发范式","url":"https://stock-news.laohu8.com/highlight/detail?id=2649984355","media":"智通财经","labels":["corporation"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2649984355?lang=zh_cn&edition=full","pubTime":"2026-07-07 18:57","pubTimestamp":1783421872,"startTime":"0","endTime":"0","summary":"智通财经APP讯,翰思艾泰-B 发布公告,为充分发挥产学研结合的优势,加速生物医药研发创新,公司于近日与华科—澳城大高等研究院前沿交叉研究中心正式签署了《“人工智能药物研发联合实验室”合作共建协议》。双方将依托华科前沿交叉研究中心的AI平台,以及翰思艾泰在创新药研发的丰富经验和对疾病领域的深度认知,围绕抗体发现与分子设计展开深度合作,共同打造新一代AI驱动的创新药研发范式。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://www.zhitongcaijing.com/content/detail/1464249.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"corporation","news_rank":0,"length":0,"strategy_id":0,"source":"stock_zhitongcaijing","symbols":["PBE","BK1161","WRND","GSKH","QTOC","AIPO","VTHR","AGIX","03378","IBB","BK1173","BBP","LFSC","BK4588","BK4585","ARTY","SBIO","GDOC","BK1535","CHAT"],"isVideo":false,"video":null,"gpt_icon":0}],"profile":{"websiteUrl":"http://www.hanxbio.com/","stockEarnings":[{"period":"1week","weight":-0.0759},{"period":"1month","weight":0.003},{"period":"3month","weight":-0.1416},{"period":"6month","weight":0.5673},{"period":"1year","weight":-0.1625},{"period":"ytd","weight":0.6771}],"compareEarnings":[{"period":"1week","weight":0.0086},{"period":"1month","weight":0.0473},{"period":"3month","weight":-0.0395},{"period":"6month","weight":-0.0694},{"period":"1year","weight":-0.0094},{"period":"ytd","weight":-0.0288}],"compareStock":{"symbol":"HSI","name":"恒生指数"},"description":"翰思艾泰生物医药科技(武汉)股份有限公司是一家主要从事肿瘤免疫疗法的研发的中国公司。该公司的产品管线有针对肿瘤学的临床阶段候选药物和临床前阶段候选药物,包括核心产品HX009及主要产品HX301及HX044,以及针对自身免疫和肿瘤市场的抗体偶联药物、双特异性抗体及单克隆抗体。HX009是一种自主研发的抗程序性细胞死亡蛋白1(PD-1)/信号调节蛋白α(SIRPα)双功能抗体融合蛋白。HX301是一种靶向集落刺激因子-1受体(CSF1R)、AMPK相关蛋白激酶5(ARK5)、FMS样酪氨酸激酶3(FLT-3)及细胞周期蛋白依赖性激酶4/6(CDK4/6)等关键通路的多靶点激酶抑制剂。HX044为一种新型双重功能抗细胞毒性T淋巴细胞相关蛋白4(CTLA-4)抗体SIRPα融合蛋白。","yearOnYearQuotes":[{"month":1,"riseRate":0.588235,"avgChangeRate":0.005427},{"month":2,"riseRate":0.411765,"avgChangeRate":0.008835},{"month":3,"riseRate":0.352941,"avgChangeRate":-0.021319},{"month":4,"riseRate":0.705882,"avgChangeRate":0.100651},{"month":5,"riseRate":0.352941,"avgChangeRate":0.046508},{"month":6,"riseRate":0.470588,"avgChangeRate":-0.00883},{"month":7,"riseRate":0.470588,"avgChangeRate":0.004276},{"month":8,"riseRate":0.470588,"avgChangeRate":-0.031033},{"month":9,"riseRate":0.588235,"avgChangeRate":-0.013577},{"month":10,"riseRate":0.75,"avgChangeRate":0.019136},{"month":11,"riseRate":0.625,"avgChangeRate":0.009468},{"month":12,"riseRate":0.625,"avgChangeRate":0.056179}],"exchange":"SEHK","name":"翰思艾泰-B","nameEN":"HANXBIO-B"},"APP":{"userAgent":"Mozilla/5.0 AppleWebKit/537.36 (KHTML, like Gecko; compatible; ClaudeBot/1.0; +claudebot@anthropic.com)","isDev":false,"isTTM":false,"isLaohu8Offline":false,"tenantId":"TBCN","deviceId":"web-server-community-laohu8-v3","version":"4.44.1","shortVersion":"4.44.1","platform":"web","vendor":"web","appName":"laohu8","isIOS":false,"isAndroid":false,"isTiger":false,"isTHS":false,"isWeiXin":false,"isWeiXinMini":false,"isWeiBo":false,"isQQ":false,"isBaiduSwan":false,"isBaiduBox":false,"isDingTalk":false,"isToutiao":false,"isOnePlus":false,"isHuaWei":false,"isXiaomi":false,"isXiaomiWebView":false,"isOppo":false,"isVivo":false,"isSamsung":false,"isMobile":false},"pagemeta":{"title":"翰思艾泰-B(03378)_个股概要_股票价格_最新资讯_行情走势_历史数据","description":"美港股上老虎。老虎社区提供翰思艾泰-B(03378)今日价格,行情走势,历史数据,股票概要及实时的新闻资讯,近期大事等重要参考决策数据。","keywords":"翰思艾泰-B,03378,翰思艾泰-B股票,翰思艾泰-B股票老虎,翰思艾泰-B股票老虎国际,翰思艾泰-B行情,翰思艾泰-B股票行情,翰思艾泰-B股价,翰思艾泰-B股市,翰思艾泰-B股票价格,翰思艾泰-B股票交易,翰思艾泰-B股票购买,翰思艾泰-B股票实时行情,购买美股,购买港股,港股开户,美股开户,美股交易,港股交易,开通美港股账户,老虎国际行情","social":{"og_title":"翰思艾泰-B(03378)_个股概要_股票价格_最新资讯_行情走势_历史数据","og_description":"美港股上老虎。老虎社区提供翰思艾泰-B(03378)今日价格,行情走势,历史数据,股票概要及实时的新闻资讯,近期大事等重要参考决策数据。","og_image":"https://static.tigerbbs.com/a0b84b8debbbce3b4440f7fdd5eed2e7"}}}